Biodesix
Logotype for Biodesix Inc

Biodesix (BDSX) investor relations material

Biodesix UBS Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Biodesix Inc
UBS Global Healthcare Conference summary10 Nov, 2026

Nodify opportunity and Q3 performance

  • U.S. annual incidental lung nodule estimates are now 5M–6M; Nodify CDT flags likely malignancy, while XL2 identifies likely benign nodules.

  • Q3 diagnostic testing revenue was $23M, up 16% YoY; 19,400 tests were performed, up 24%, with FY revenue still expected to exceed $100M.

  • Q3 performance was affected by lower sales capacity and greater-than-expected primary-care seasonality; October brought the strongest new-physician acquisition month and improving existing-customer orders.

  • Primary care represents 15% of patient volume and about 50% of the market; its decisions focus on surveillance versus specialist referral, unlike pulmonologists’ procedure decisions.

  • Adding CDT for 4–8 mm nodules can lower average ASP because it is lower priced than XL2, while supporting earlier cancer detection and increased ordering of both tests; gross margin remained above 80% for six consecutive quarters.

Commercial execution and care pathways

  • Q3 average sales headcount was 101; plans were to reach ~110 and target ~115 by year-end, hiring 6–8 reps per quarter to match recruiting and training capacity.

  • Reps historically begin covering their costs within a quarter and typically reach stride in 6–9 months; some continue growing after several years in the field.

  • CHEST introduced a structured framework for nodule-management programs, identifying biomarkers as a key component; distribution to members and implementation work are underway, including two West Coast health systems.

  • Formal guideline updates were rumored for Q1–Q2 2027; broader use of automated patient identification, algorithmic ordering, blood-draw access and electronic integrations could reduce reliance on high-touch sales and lift orders per customer.

  • Health-system economics center on finding missed cancers and avoiding unnecessary interventions; health-economic evidence has supported pricing and Medicare rates, with alternative payer models under discussion.

Digital diagnostics and data strategy

  • A radiomics-based lung nodule assessment developed with Vanderbilt is targeted for commercialization in 2028 and is intended to complement blood-based Nodify tests with high-specificity imaging signals.

  • The STRATIFY study, announced at CHEST, will assess clinical utility of Nodify CDT and XL2 and validate a radiomic classifier alongside the blood test; study findings are expected to inform the optimal workflow and patient populations.

  • First digital-platform data were expected at RSNA within weeks, followed shortly thereafter by an initial publication with test performance data.

  • STRATIFY will combine blood samples and CT scans; the resulting multimodal dataset and Diagnostic Cortex machine-learning platform could support further lung diagnostics and potential biopharma collaborations.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Biodesix earnings date

Logotype for Biodesix Inc
Q4 202626 Feb, 2027
Biodesix
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Biodesix earnings date

Logotype for Biodesix Inc
Q4 202626 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Biodesix Inc. is a diagnostic company specializing in blood-based tests for lung diseases, including cancer and other respiratory conditions. The company utilizes multiple technologies such as genomics and proteomics to develop diagnostic and monitoring solutions. Its offerings are intended for use in clinical decision support. The company is headquartered in Boulder, Colorado, and its shares are listed on the NASDAQ.